Video: Knock on Wood| Webinar: ACR/CHEST ILD Guidelines in Practice
fa-facebookfa-linkedinfa-youtube-playfa-rss

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: methotrexate

Duke University Names Dr. Megan Clowse to Lead Rheumatology Division

Linda Childers  |  February 10, 2024

In October 2023, Megan E.B. Clowse, MD, MPH, a renowned expert in the field of rheumatology and immunology, was named the new chief of the Division of Rheumatology and Immunology at Duke University School of Medicine, Durham, N.C. Dr. Clowse, who serves as an associate professor of medicine in Duke’s Division of Rheumatology and Immunology…

Filed under:CareerProfiles Tagged with:Dr. Megan ClowseMovers & Shakerspregnancy

3 AC&R Study Summaries: Prescribing Patterns, PMR & Glucocorticoids, & Infection Screening

Arthritis Care & Research  |  February 9, 2024

A Shift in Prescribing Patterns Safety issues prompt discontinuation of tofacitinib By Stephanie Song, MD, & Joshua F. Baker, MD, MSCE Why was this study done? The ORAL Surveillance study highlighted risks of cardiac events, thromboembolism (VTE) and malignancy associated with use of Janus kinase inhibitors (JAKi). We sought to determine the impact of safety…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch ReviewsResearch RheumRheumatoid Arthritis Tagged with:GlucocorticoidsInfectionJAK inhibitorsPolymyalgia RheumaticaReading Rheumsteroid-sparing therapiesTofacitinib

Polymyalgia Rheumatica: New Tricks for an Old Disease

Desh Nepal, MD, Sebastian E. Sattui, MD, MS, & Michael Putman, MD, MS  |  January 29, 2024

Originally posted Feb. 13, 2023; reposted in conjunction with publication of the PMR supplement to the February 2024 issue of The Rheumatologist. PHILADELPHIA—Polymyalgia rheumatica (PMR) is a chronic inflammatory condition that almost exclusively affects individuals older than 50.1 First described in 1888, PMR has been a recognized rheumatic disease since at least 1957. Diagnosing the…

Filed under:ACR ConvergenceConditionsMeeting ReportsSoft Tissue Pain Tagged with:ACR Convergence 2022Disease-modifying antirheumatic drugs (DMARDs)GlucocorticoidsIL-6IL-6 inhibitorsimagingPMR FocusRheumPolymyalgia Rheumatica

How to Treat Refractory Polymyalgia Rheumatica

Katie Robinson  |  January 25, 2024

Patients with polymyalgia rheumatica (PMR) who had relapsed while tapering glucocorticoid therapy were more likely to achieve sustained remission at one year and have a lower glucocorticoid exposure if they were treated with sarilumab (Kevzara) plus a rapid, 14-week glucocorticoid taper than if they received placebo plus a standard, 52-week glucocorticoid taper. This is according…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:glucocorticoid resistantIL-6IL-6 inhibitorsPMR FocusRheumPolymyalgia RheumaticaResearch Reviewsarilumab

Study: Most Patients with PMR Aren’t Getting Steroid-Sparing Agents in First 2 Years

Katie Robinson  |  January 25, 2024

A minority of patients with polymyalgia rheumatica (PMR) who were new to rheumatology practice were prescribed steroid-sparing agents through two years of follow-up. This is according to a large, U.S.-based cohort study, published in Arthritis Care & Research, which also found that nearly two-thirds of the patients remained on glucocorticoids beyond one year.1 “Our study…

Filed under:Biologics/DMARDsConditionsDrug UpdatesOther Rheumatic ConditionsResearch Rheum Tagged with:GlucocorticoidsMethotrexatePMR FocusRheumPolymyalgia RheumaticaResearch Reviewsteroid-sparing therapies

The Risk of Cardiovascular Events in Patients with RA & More Explored in 3rd Plenary Session

Samantha C. Shapiro, MD  |  January 19, 2024

SAN DIEGO—In one presentation at Plenary Session 3, ACR Convergence 2023, Beth Wallace, MD, MSc, a staff physician at the VA Ann Arbor Healthcare System, Michigan, and an assistant professor at the University of Michigan, Ann Arbor, shared important data on the relationship between time-dependent cumulative glucocorticoid exposure and major adverse cardiovascular events (MACE) in a cohort of veterans with rheumatoid arthritis (RA).

Filed under:ACR ConvergenceConditionsMeeting ReportsRheumatoid Arthritis Tagged with:ACR Convergence 2023Lupus nephritisRA Resource Center

The 2023 ARP Merit Awards

Patrice Fusillo  |  January 10, 2024

SAN DIEGO—During ACR Convergence 2023 in November, the ACR and the ARP honored a group of distinguished individuals who have made significant contributions to rheumatology research, education and patient care. This month, The Rheumatologist profiles the recipients of the ARP Merit Awards and ARP Master class, recognizing outstanding contributions to the field of rheumatology. The…

Filed under:ACR ConvergenceAwardsCareerMeeting Reports Tagged with:ACR Convergence 2023Association of Rheumatology Professionals (ARP)

An Interview with Expert Clinician Dr. Fred Wigley

Jason Liebowitz, MD, FACR  |  January 10, 2024

Rheumatologists who are outstanding researchers, educators and/or clinicians, who provide consistently exceptional care to patients, who have achieved a level of  distinction in the field and who serve as role models for colleagues and trainees are highlighted in this recurring series. Fred Wigley, MD, MACR, is the Martha McCrory Professor of Medicine at the Johns…

Filed under:OpinionProfiles Tagged with:Dr. Fred WigleyRole Models in Rheumatology

Going Viral: How to Find & Engage Your Audience to Become a Podcast Celebrity

Jason Liebowitz, MD, FACR  |  January 9, 2024

A panel of experts, including ACR on Air Host Jonathan Hausmann, MD, provided tips and insights into creating a podcast and engaging with an audience.

Filed under:ACR ConvergenceCareerMeeting Reports Tagged with:ACR Convergence 2023ACR on Airpodcast

Rheum in the Court, Law in the Clinic: Health Policy in Global Rheumatology

Glen Rodman  |  December 6, 2023

SAN DIEGO—At ACR Convergence 2023, panelists presented information concerning several policy issues that affect rheumatologists & their patients, including abortion access & the WHO’s Essential Medicine List.

Filed under:ACR ConvergenceConditionsGuidanceLegislation & AdvocacyLegislation & AdvocacyMeeting ReportsMeeting ReportsPediatric ConditionsProfessional Topics Tagged with:ACR Convergence 2023Juvenile Arthritis (JIA)reproductive rights

  • « Previous Page
  • 1
  • …
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 105
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
fa-facebookfa-linkedinfa-youtube-playfa-rss
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences